Spatial hindrancebasedpro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy2025-11-14下載專區 / 最新消息Read MoreSpatial hindrancebasedpro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy
Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy2025-05-27下載專區 / 最新消息Read MoreProtease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
Specific-activation-of-pro-Infliximab-enhances-selectivity-and-safety-of-rheumatoid-arthritis-therapy2021-10-14下載專區 / 最新消息Read MoreSpecific-activation-of-pro-Infliximab-enhances-selectivity-and-safety-of-rheumatoid-arthritis-therapy
Get In Touch We can't wait to hear from you！ Contact Us +886 7 311 1577 ｜台北辦公室｜ 臺北市南港區園區街3號17樓 ｜高雄辦公室｜ 高雄市三民區十全一路100號（第一教學大樓12樓1207室） 首頁 關於碩準 核心技術 產品研發線 抗體鎖平台 最新消息 合夥人及投資人 聯絡我們 Stay Connected Lock Antibodies, Unluck Health! Lock Antibodies, Unluck Health!
